Idelalisib-associated colitis

American Journal of Surgical Pathology

Volumn 39, Issue 12, 2015, Pages 1661-1667

  Weidner, Anna Sophie ^a   Panarelli, Nicole C ^a   Geyer, Julia T ^a   Bhavsar, Erica B ^a   Furman, Richard R ^a   Leonard, John P ^a   Jessurun, Jose ^a   Yantiss, Rhonda K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CAL 101; chemotherapy; colitis; GS 1101; idelalisib; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; IDELALISIB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

AGED; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOPSY; CHEMICALLY INDUCED; CHEMISTRY; COLITIS; COLON; COLONOSCOPY; DIARRHEA; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; LYMPHOMA, NON-HODGKIN; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS; BIOPSY; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLITIS; COLON; COLONOSCOPY; DIARRHEA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PURINES; QUINAZOLINONES; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84948715031     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000522     Document Type: Article

References (11)

1. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014; 123: 3398-3405
2. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117: 591-594
3. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014; 123: 3406-3413
4. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123: 3390-3397
5. Gopal AK, Kahl BS, de Vos S, et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370: 1008-1018
6. Common Terminology Criteria for Adverse Events. (CTCAE), v 4.0 [NCI/NIH web site]. May 29, 2009. Available at: evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed January 1, 2015
7. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997-1007
8. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002; 297: 1031-1034
9. Uno JK, Rao KN, Matsuoka K, et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110d. Gastroenterology. 2010; 139: 1642-1653
10. Soldini D, Gaspert A, Montani M, et al. Apoptotic enteropathy caused by antimetabolites and TNF-A antagonists. J Clin Pathol. 2014; 67: 582-586
11. Star KV, Ho VT, Wang HH, et al. Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol. 2013; 37: 1319-1328.